TY - T1的无症状的颈动脉狭窄的颈动脉血管再生和医疗管理:CREST-2更新(p1.3 - 060) JF -神经学乔-神经学六世- 92 - 15补充SP - p1.3 - 060 AU -詹姆斯Meschia盟Brajesh Lal AU -乔治·霍华首页德盟-谭雅图兰AU -加里Roubin AU -罗伯特·布朗AU -凯文·巴雷特盟Seemant查图尔维迪盟- Marc Chimowitz AU -巴特Demaerschalk AU -维吉尼亚霍华德非盟-约翰·休斯顿AU -罗纳德•拉扎尔非盟-韦斯利·摩尔盟——克劳迪娅Moy盟珍妮弗Voeks AU -托马斯王硕Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p1.3 - 060. -抽象N2 -目的:描述当前状态的招聘阶段CREST-2审判。背景:超过100000的颈动脉血管再生程序完成每年在美国无症状的颈动脉狭窄。颈动脉内膜切除手术的安全性(CEA)和颈动脉支架植入(CAS),和药物治疗的疗效改变动脉粥样硬化的进展有所改善。因此,之前的随机试验的适用性受到质疑。设计/方法:CREST-2的目的是比较CEA和密集的医疗管理(IMM)与IMM (n = 1240),中科院和IMM与IMM (n = 1240),通过两个并行随机临床试验≈120医疗中心。复合主要结果是任何中风或死亡后44天内随机化或侧缺血性中风之后4年。认知功能是一个次要的结果。IMM定向集中,包括严格控制血压(收缩压目标& lt; 130毫米汞柱)和胆固醇(低密度脂蛋白目标& lt;70 mg / dl)以及生活方式的指导。结果:截至2018年9月20日,选址委员会已经批准了185个站点,其中144已经准许入学。123网站注册至少一个病人。 The Surgical and Interventional Management Committees have credentialed 400 surgeons and 175 interventionists. An additional 120 interventionists have been approved to submit additional cases via the CREST-2 Companion Registry, which provides a CMS-reimbursed pathway for full credentialing in CREST-2. As of October 17, 2018, 1188 patients have been randomized: 612 (51%) patients in the endarterectomy trial and 576 (49%) patients in the stent trial.Conclusions: CREST-2 is designed to identify the best approach for asymptomatic carotid stenosis. An update will be provided regarding the numbers of patients randomized, centers certified, as well as surgeons and interventionists fully approved. The Registry will provide the option of CAS while enhancing interventionists’ credentials for participation in CREST-2.Disclosure: Dr. Meschia has nothing to disclose. Dr. Lal has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Turan has nothing to disclose. Dr. Roubin has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Barrett has nothing to disclose. Dr. Chaturvedi has received personal compensation in an editorial capacity for NEJM Journal Watch Neurology. Dr. Chaturvedi has received research support from Boehringer Ingelheim. Dr. Chimowitz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bristol Myers Squibb. Dr. Demaerschalk has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Huston has nothing to disclose. Dr. Lazar has nothing to disclose. Dr. Moore has nothing to disclose. Dr. Moy has nothing to disclose. Dr. Voeks has nothing to disclose. Dr. Brott has nothing to disclose. ER -